Abstract
Drug repurposing, the use of established drugs in new, previously unrelated indications, offers many potential advantages, such as lower development costs and higher success probabilities in clinical trials, which is thought to be attractive especially for orphan indications. This analysis was conducted to assess the success of repurposed drugs (RD) in German HTA procedures and subsequent price negotiations based on AMNOG.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
